Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs

Archives of Pharmacal Research

Volumn 27, Issue 6, 2004, Pages 662-669

  Cho, Hoon ^b   Chung, Yongseog ^a  

^a Chungbuk National University   (South Korea)

^b Kuhnil Pharmaceutical Co Ltd   (South Korea)

Author keywords

Cyclosporine; PEG; Polymer conjugate; Prodrug

Indexed keywords

BUFFER; CYCLOSPORIN; DRUG CARRIER; MACROGOL DERIVATIVE; MONOMETHOXYPOLYETHYLENE GLYCOL; PRODRUG; WATER;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG STABILITY; HALF LIFE TIME; HUMAN; HYDROLYSIS; IN VITRO STUDY; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; PH; RAT; SOLUBILITY; SPRAGUE DAWLEY RAT; TIME;

ADMINISTRATION, ORAL; ANIMALS; BUFFERS; CYCLOSPORINE; DRUG CARRIERS; DRUG STABILITY; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; LIVER; POLYETHYLENE GLYCOLS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TIME FACTORS; WATER;

EID: 16444381263     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02980167     Document Type: Article

References (14)

1. Abella, I., Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Transplant Proc., 28, 3131 (1996).
2. Diasio, R. B. and LoBuglio. A. F., Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman, J. G., Goodman, L. S., Gillman, A., Limbird, L. E., eds. Goodman and Gillmans the pharmacological basis of therapeutics [ed. 9]. New York, McGraw-Hill, 1291 (1996).
3. Drewe, J., Beglinger, C., and Kissel, T., The absorption site of cyclosporin in the human gastrointestinal tract. Br. J. Clin. Pharmacol., 33(1), 39-43 (1992).
4. Fahr, A., Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet., 24(6), 472-495 (1993). Review.
5. Faulds, D., Goa, K. L., and Benfield, P., Cyclosporine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, 45, 953 (1993).
6. Maeda, H., SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev., 6, 181-202 (1991).
7. Maeda, H., Seymour, L. W., and Miyamoto, Y., Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem., 3, 351-362 (1992).
8. Matthew, A. E., Mejillano, M. R., Nath, J. P., Himes, R. H., and Stella, V. J., Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem., 35, 145-157 (1992).
9. McEvoy, G. K., ed. AHFS drug information. Bethesda, M. D., American Society of Health-System Pharmacists, 3057 (1998).
10. Noble, S. and Markham, A., Cyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs, 50, 924 (1995).
11. Noguchi, Y., Wun, J., Duncan, R., Strohalm, R., Ulbrich, K., Akaike, T., and Maeda, H., Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89, 307-314 (1998).
12. Shibata, N., Morita, K., Ono, T., Nishikawa, S., Kinoshita, M., Kawakita, S., Takada, K., Muranishi, S., and Shimakawa, H., Effects of diltiazem on rheological properties of human blood. Journal of pharmacobio-dynamics, 11(3), 175-180 (1988).
13. Strom, T. B. and Tilney, N. L., Immunobiology and immunopharmacology of graft rejection. In: Schrier, R. W., Gottschalk, C. W., eds. Diseases of the Kidney [ed 5]. Boston, Little, Brown, 2879 (1993).
14. Ymaoka, T., Tabata, Y., and Ikada, Y., Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J. Pharm. Sci., 83, 601-606 (1994).